Ignite Creation Date:
2024-05-06 @ 7:06 PM
Last Modification Date:
2024-10-26 @ 3:00 PM
Study NCT ID:
NCT05892146
Status:
RECRUITING
Last Update Posted:
2023-06-07
First Post:
2023-05-26
Brief Title:
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
Sponsor:
National Cheng-Kung University Hospital
Organization:
National Cheng-Kung University Hospital
Study Overview
Official Title:
Strategy Therapy on Early Phase Cancer Therapeutics-Related Cardiac Dysfunction Patients
Status:
RECRUITING
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators use the cancer registration system of National Cheng Kung University Hospital to timely screen and evaluate those patients having breast cancer or lymphoma to enroll patients to participate in this clinical trial The investigators planned an earlier initiation of SacubitrilValsartan treatment on breast cancer and lymphoma patients before the chemotherapy and starting therapeutic intervention by SacubitrilValsartan once the heart damage sign appeared via novel echocardiography The investigators aim to assess the protective and therapeutic benefit of cardioprotective drugs on the cardiotoxicity of anti-cancer therapy
Detailed Description:
The investigators use the cancer registration system of National Cheng Kung University Hospital to timely screen and evaluate those patients having breast cancer or lymphoma to enroll patients to participate in this clinical trial Also the Patient Recruitment System support to complete the patients database The investigators cooperate with other hospitals in South Taiwan to carry on an early phase clinical trial named Strategy by novel anti-heart failure therapy on early phase Cancer Therapeutics-Related Cardiac Dysfunction CTRCD patients focusing on the either preventive strategy to earlier initiation of SacubitrilValsartan treatment on breast cancer and lymphoma patients before the chemotherapy and starting therapeutic intervention by SacubitrilValsartan once the heart damage sign appeared via novel echocardiography and collect clinical and genetic information from the enrolled patients These patients randomized into 2 groups cardioprotective drug vs placebo The regular assessment of cardiac function is as following baseline prior to anti-cancer treatment and every 3 months Thereafter The investigators aim to assess the protective andor therapeutic benefit of cardioprotective drugs on the cardiotoxicity of anti-cancer therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None